Evaluate the ability of ranolazine to favorably modify thrombogenic, inflammatory, lipogenic, oxidative stress and hormonal biomarkers in a relatively short period of time in a group of ethnically diverse women with chronic stable angina and metabolic syndrome. Evaluate the ability of ranolazine to favorably decrease angina frequency and nitroglycerine use in a relatively short time in this group of patients.